Convergent Therapeutics

Convergence Pharmaceuticals Limited provides biotechnology products and services. The Company focuses on developing analgesics medicines including a small molecule sodium channel blocker for the treatment of chronic pain.In February 2021, AIkido Pharma announced that the Company executed a Two Million Dollar Convertible Promissory Note Purchase Agreement with Convergent Therapeutics.In May 2023, Convergent Therapeutics Inc announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management